Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication protects patients with peanut allergies

11.03.2003


Study shows life-threatening reactions from accidental ingestion can be avoided



A new medication could help most people with peanut allergies avoid life-threatening allergic reactions, according to a report in the March 14 issue of the New England Journal of Medicine. A research team led by Donald Leung, M.D., Ph.D. of National Jewish Medical and Research Center, and Hugh Sampson, M.D. of Mount Sinai School of Medicine, found that treatment with an anti-IgE antibody raised the average level at which study participants began reacting to peanuts from about half a peanut to almost nine peanuts. Researchers estimate that most of the 50-100 annual fatal reactions to peanuts occur after an allergic person accidentally eats the equivalent of just one to two nuts. The researchers also presented their findings March 10 in Denver at the annual meeting of the American Academy of Allergy, Asthma & Immunology IgE is the molecule that binds to a group of cells called mast cells, which then trigger the allergic response. Food allergy symptoms can range from nausea and itching to anaphylactic shock and death. TNX-901, the treatment used in this study, is a genetically engineered antibody made by Tanox Inc. that binds to the IgE molecule and prevents it from triggering the allergic response.

"Our results indicate that the anti-IgE antibody could become the first preventive medicine for peanut allergies," said Dr. Leung. "If future studies bear out this initial promise, anti-IgE could not only save lives, but help lift a cloud of fear that people with peanut allergies live under every time they eat."


Approximately 1.5 million people in the U.S. have peanut allergy, the leading cause of severe allergic reactions. Each year, thousands of people rush to hospital emergency rooms, and approximately 50 to 100 people die after accidentally eating peanuts. Strict avoidance is the only means of preventing an allergic reaction. But, that can be difficult to impossible, especially, since food labels do not always mention tiny amounts of peanuts that are found in some foods. An earlier study found that fatal reactions can occur after such difficult to avoid situations as eating a tuna sandwich made with a knife that had not been thoroughly cleaned after spreading peanut butter or eating cookies that were made on factory equipment that had earlier been used to make other cookies with peanuts. Existing medications, including epinephrine, antihistamines, bronchodilators, and charcoal pills, are taken only after the peanuts have been eaten and are not always effective.

"Anti-IgE therapy is not a cure for peanut allergy," said Dr. Sampson. "We believe that patients would have to continue the injections for the benefits to persist and they still would need to be careful about what they eat. But, because the amount they could consume without serious reaction would be greatly increased, the fear of accidental ingestion that detracts from quality of life for many patients would be eliminated. These are very promising results."

Blocking IgE is considered a major advance because it inhibits the allergic response at an earlier stage than other medicines, effectively stopping it before it begins. A slightly different anti-IgE molecule has shown promise in treating severe hay fever and asthma. In the current randomized, double-blinded, placebo-controlled study, 82 people ages 12 to 60 with severe peanut allergy were given four injections at monthly intervals of either a placebo or one of three doses (150 mg, 300 mg , or 450mg) of TNX-901. Before the trial began, each patient underwent an oral food challenge with increasing doses of peanut flour and a food challenge with a placebo to establish their sensitivity to peanuts. Patients were monitored closely during the challenges. Each challenge was halted and treatment begun as soon as a doctor determined that an allergic reaction had begun. Symptoms that commonly signaled an allergic reaction included nausea, abdominal pain, vomiting, throat or chest tightness, wheezing, itching, cough, and hives. Each patient’s threshold sensitivity to peanuts was considered the amount of peanut flour consumed immediately before the challenge was stopped. TNX-901 was well tolerated with no significant side effects.

Blood levels of IgE were measured before the injections began and periodically throughout the test. Two to four weeks after the final injection, patients underwent one more food challenge with peanut flour.

TNX-901 raised patients’ threshold sensitivity to peanut flour in a dose-responsive manner. The threshold sensitivity for patients receiving the largest dose (450 mg) of TNX-901 increased from an average of 177 mg to 2,805 mg. The average accidental ingestion is estimated to one to two peanuts or about 325 mg to 650 mg. Nearly a quarter of the patients receiving the highest dose of TNX-901 consumed 8,000 mg, or about 24 peanuts, with no reaction. Many patients still reacted to peanuts even after the injections. But on average, they could eat more peanuts without a reaction, and reacted less vigorously to the peanuts they did eat.


###
Other medical centers participating in the trial included Mayo Clinic in Rochester, MN; Arkansas Children’s Hospital in Little Rock, AK; and Children’s Hospital in Boston, MA.

William Allstetter | EurekAlert!
Further information:
http://www.njc.org/

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>